サマリー

主な内容
北米の創薬市場は、予測期間である2022年から2030年の間にCAGR6.14%を記録すると予測されています。需要の急増は、希少疾患や女性の健康など、いくつかの治療分野の優先順位が高まっていることに起因しています。
地域別インサイト
北米の創薬市場の成長分析には、米国とカナダを評価対象としています。カナダでは、創薬開発市場は比較的小さいですが、複数のレベルでの関連性と開発の面で緩やかな成長が予測されています。例えば、カナダの製薬会社であるSunshine Biopharmaは、抗ウイルス薬と腫瘍薬の研究、開発、商品化に取り組んでいます。
また、カナダに拠点を置くいくつかのバイオテクノロジー企業や学術機関の発明やコンセプトは、がんや感染症の治療における薬物療法の状況を改善する、不可欠なドラッグデリバリー製品の開発を促進しました。さらに、製薬会社の広範な研究開発活動は、パートナーシップを通じ、中小企業やベンチャーファンドへの追加投資を可能にしています。その上、カナダにおける医薬品売上高は2001年から2015年の間に倍増し、病院と小売の売上高はそれぞれ医薬品売上高全体の12.5％と87.5％を占めています。こうした動きは、市場の成長に寄与しています。
競争力のある洞察
市場の主要企業には、Icon Plc、Merck & Co Inc、Johnson & Johnson、IQVIA Holdings Incなどが挙げられます。
当社のレポート提供は以下の通りです。
- 市場全体に関する主要な知見を探る
- 市場力学（推進要因、抑制要因、機会、課題）の戦略的な内訳
- 全セグメント、サブセグメント、地域の3年分の過去データとともに、最低9年間の市場予測を掲載
- 市場細分化により、主要セグメントを徹底的に評価し、その市場推定値を提示
- 地域別分析。言及された地域および国別セグメントの評価とその市場占有率
- 主要な分析ポーターの5つの力分析、ベンダーランドスケープ、オポチュニティマトリックス、キーバイヤークライテリア、など。
- コンペティティブ・ランドスケープは、主要企業を要因や市場シェアなどに基づいて理論的に説明したものです。
- 企業プロファイリング。詳細な企業概要、提供する製品/サービス、SCOT分析、最近の戦略的展開など

ページTOPに戻る

目次

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. GROWING R&D FOR TACKLING SEVERAL DISEASES
3.1.2. TECHNOLOGICAL ADVANCEMENTS
3.2. KEY RESTRAINTS
3.2.1. EXTENSIVE TIME-CONSUMING PROCESS
3.2.2. HIGHLY REGULATED MARKET
3.2.3. PROJECT FEASIBILITY AND SUCCESS RATE
4. KEY ANALYTICS
4.1. IMPACT OF COVID-19 ON DRUG DISCOVERY MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. DRUG DISCOVERY AND DEVELOPMENT PROCESS
4.5.1. DRUG DISCOVERY AND DEVELOPMENT
4.5.2. PRECLINICAL RESEARCH
4.5.3. CLINICAL RESEARCH
4.5.4. REGULATORY AUTHORITY REVIEW
4.5.5. POST MARKET SAFETY MONITORING
4.6. REGULATORY FRAMEWORK
5. MARKET BY DRUG TYPE
5.1. SMALL MOLECULE DRUG
5.2. BIOLOGIC DRUG
6. MARKET BY SERVICE
6.1. CHEMICAL SERVICES
6.2. DRUG METABOLISM AND PHARMACOKINETICS SERVICES
6.3. BIOLOGICAL SERVICES
6.4. OTHER PHARMACEUTICAL SERVICES
7. MARKET BY END-USER
7.1. PHARMACEUTICAL COMPANIES
7.2. CONTRACT RESEARCH ORGANIZATIONS
7.3. RESEARCH INSTITUTES
7.4. OTHER END-USERS
8. MARKET BY TECHNOLOGY
8.1. HIGH THROUGHPUT SCREENING
8.2. SPECTROSCOPY
8.3. COMBINATORIAL CHEMISTRY
8.4. BIOCHIPS
8.5. PHARMACOGENOMICS AND PHARMACOGENETICS
8.6. BIOINFORMATICS
8.7. METABOLOMICS
8.8. NANOTECHNOLOGY
8.9. OTHER TECHNOLOGIES
9. GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1. MARKET SIZE & ESTIMATES
9.1.2. KEY GROWTH ENABLERS
9.1.3. KEY CHALLENGES
9.1.4. KEY PLAYERS
9.1.5. COUNTRY ANALYSIS
9.1.5.1. UNITED STATES
9.1.5.2. CANADA
10. COMPETITIVE LANDSCAPE
10.1. KEY STRATEGIC DEVELOPMENTS
10.1.1. MERGERS & ACQUISITIONS
10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
10.1.3. PARTNERSHIPS & AGREEMENTS
10.1.4. BUSINESS EXPANSIONS & DIVESTITURES
10.2. COMPANY PROFILES
10.2.1. AGILENT TECHNOLOGIES INC
10.2.2. ASTRAZENECA PLC
10.2.3. BAYER AG
10.2.4. CHARLES RIVER LABORATORIES INTERNATIONAL INC
10.2.5. ELI LILLY AND COMPANY
10.2.6. EVOTEC SE
10.2.7. GLAXOSMITHKLINE PLC
10.2.8. ICON PLC
10.2.9. IQVIA HOLDINGS INC
10.2.10. JOHNSON & JOHNSON
10.2.11. MERCK & CO INC
10.2.12. NOVARTIS AG
10.2.13. PFIZER INC
10.2.14. ROCHE AG





LIST OF TABLES
TABLE 1: MARKET SNAPSHOT - NORTH AMERICA DRUG DISCOVERY
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: NORTH AMERICA DRUG DISCOVERY MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 4: NORTH AMERICA DRUG DISCOVERY MARKET, BY DRUG TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 5: NORTH AMERICA DRUG DISCOVERY MARKET, BY SERVICE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 6: NORTH AMERICA DRUG DISCOVERY MARKET, BY SERVICE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 7: NORTH AMERICA DRUG DISCOVERY MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 8: NORTH AMERICA DRUG DISCOVERY MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 9: NORTH AMERICA DRUG DISCOVERY MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 10: NORTH AMERICA DRUG DISCOVERY MARKET, BY TECHNOLOGY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 11: NORTH AMERICA DRUG DISCOVERY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 12: NORTH AMERICA DRUG DISCOVERY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 13: LEADING PLAYERS OPERATING IN NORTH AMERICA DRUG DISCOVERY MARKET
TABLE 14: LIST OF MERGERS & ACQUISITIONS
TABLE 15: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 16: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 17: LIST OF BUSINESS EXPANSIONS & DIVESTITURES



LIST OF FIGURES
FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER’S FIVE FORCES ANALYSIS
FIGURE 3: OPPORTUNITY MATRIX
FIGURE 4: DRUG DISCOVERY AND DEVELOPMENT PROCESS
FIGURE 5: NORTH AMERICA DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2021
FIGURE 6: NORTH AMERICA DRUG DISCOVERY MARKET, BY SMALL MOLECULE DRUG, 2022-2030 (IN $ MILLION)
FIGURE 7: NORTH AMERICA DRUG DISCOVERY MARKET, BY BIOLOGIC DRUG, 2022-2030 (IN $ MILLION)
FIGURE 8: NORTH AMERICA DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY SERVICE, IN 2021
FIGURE 9: NORTH AMERICA DRUG DISCOVERY MARKET, BY CHEMICAL SERVICES, 2022-2030 (IN $ MILLION)
FIGURE 10: NORTH AMERICA DRUG DISCOVERY MARKET, BY DRUG METABOLISM AND PHARMACOKINETICS SERVICES, 2022-2030 (IN $ MILLION)
FIGURE 11: NORTH AMERICA DRUG DISCOVERY MARKET, BY BIOLOGICAL SERVICES, 2022-2030 (IN $ MILLION)
FIGURE 12: NORTH AMERICA DRUG DISCOVERY MARKET, BY OTHER PHARMACEUTICAL SERVICES, 2022-2030 (IN $ MILLION)
FIGURE 13: NORTH AMERICA DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021
FIGURE 14: NORTH AMERICA DRUG DISCOVERY MARKET, BY PHARMACEUTICAL COMPANIES, 2022-2030 (IN $ MILLION)
FIGURE 15: NORTH AMERICA DRUG DISCOVERY MARKET, BY CONTRACT RESEARCH ORGANIZATIONS, 2022-2030 (IN $ MILLION)
FIGURE 16: NORTH AMERICA DRUG DISCOVERY MARKET, BY RESEARCH INSTITUTES, 2022-2030 (IN $ MILLION)
FIGURE 17: NORTH AMERICA DRUG DISCOVERY MARKET, BY OTHER END-USERS, 2022-2030 (IN $ MILLION)
FIGURE 18: NORTH AMERICA DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2021
FIGURE 19: NORTH AMERICA DRUG DISCOVERY MARKET, BY HIGH THROUGHPUT SCREENING, 2022-2030 (IN $ MILLION)
FIGURE 20: NORTH AMERICA DRUG DISCOVERY MARKET, BY SPECTROSCOPY, 2022-2030 (IN $ MILLION)
FIGURE 21: NORTH AMERICA DRUG DISCOVERY MARKET, BY COMBINATORIAL CHEMISTRY, 2022-2030 (IN $ MILLION)
FIGURE 22: NORTH AMERICA DRUG DISCOVERY MARKET, BY BIOCHIPS, 2022-2030 (IN $ MILLION)
FIGURE 23: NORTH AMERICA DRUG DISCOVERY MARKET, BY PHARMACOGENOMICS AND PHARMACOGENETICS, 2022-2030 (IN $ MILLION)
FIGURE 24: NORTH AMERICA DRUG DISCOVERY MARKET, BY BIOINFORMATICS, 2022-2030 (IN $ MILLION)
FIGURE 25: NORTH AMERICA DRUG DISCOVERY MARKET, BY METABOLOMICS, 2022-2030 (IN $ MILLION)
FIGURE 26: NORTH AMERICA DRUG DISCOVERY MARKET, BY NANOTECHNOLOGY, 2022-2030 (IN $ MILLION)
FIGURE 27: NORTH AMERICA DRUG DISCOVERY MARKET, BY OTHER TECHNOLOGIES, 2022-2030 (IN $ MILLION)
FIGURE 28: NORTH AMERICA DRUG DISCOVERY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
FIGURE 29: UNITED STATES DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 30: CANADA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)